Left ventricular remodelling following experimental myocardial infarction

Area of Science:

• Cardiovascular Physiology
• Cardiac Remodeling Research
• Pharmacological Intervention Models

Background:

• Experimental myocardial infarction (MI) models cardiac overload, leading to left ventricle insufficiency.
• Cardiac remodeling involves proteolytic activity, fibroblast proliferation, and changes in healthy muscle phenotype.
• Peripheral vascular changes are linked to pressor and dilator system imbalances.

Purpose of the Study:

• To investigate the relationship between infarct size and cardiac/peripheral changes in a myocardial infarction model.
• To evaluate the efficacy of converting enzyme inhibition in mitigating the effects of experimental myocardial infarction.
• To identify biomarkers indicative of cardiac stress and remodeling.

Main Methods:

• Induction of experimental myocardial infarction to create a model of cardiac overload.
• Measurement of left ventricle insufficiency, right ventricular hypertrophy, and arterial pressure.
• Analysis of atrial natriuretic factor (ANF) levels, urinary cyclic guanosine monophosphate (cGMP), myosin isoenzymes, and subendocardial collagen.
• Assessment of peripheral pressor system activation, including renin-angiotensin system and vasopressin.
• Administration of converting enzyme inhibitors to assess therapeutic effects.

Main Results:

• Cardiac and peripheral changes, including ventricular hypertrophy and arterial pressure drop, are proportional to infarct size.
• Biomarkers such as increased type V3isomyosin, subendocardial collagen, and atrial natriuretic factor (ANF) correlate with infarct size.
• Massive infarcts lead to activation of pressor systems, including increased renin and vasopressin.
• Converting enzyme inhibition reduces cardiac load, arterial pressure, and reverses hypertrophy and fibrosis.
• Therapeutic benefits of converting enzyme inhibition are limited when initial cardiac material loss exceeds 40%.

Conclusions:

• Infarct size is a critical determinant of cardiac remodeling and functional decline.
• Converting enzyme inhibition demonstrates therapeutic potential in experimental myocardial infarction but has limitations.
• Biomarkers like ANF and urinary cGMP can effectively monitor cardiac stress and remodeling extent.